Barclays Portfolio holdings
Barclays is a British universal bank whose roots go back to 1690, when the Quakers John Freame and Thomas Gould started a goldsmith banking business in London. The Barclays name came into the business in 1736, when James Barclay, son-in-law of founder John Freame, became a partner. Barclays launched the UK's first credit card, Barclaycard, in 1966, and in 1967 put the world's first cash machine in a branch in Enfield. In 2008 Barclays bought the North American operations of Lehman Brothers, and in 2009 it sold its Barclays Global Investors unit, home of the iShares ETFs, to BlackRock. It runs five divisions: UK consumer banking, UK corporate banking, private banking and wealth management, an investment bank and a US consumer bank.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$17.5B |
| 2 |
NVIDIA
NVDA
|
+$2.7B |
| 3 |
Intel
INTC
|
+$1.98B |
| 4 |
Broadcom
AVGO
|
+$1.46B |
| 5 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$1.11B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI Emerging Markets ETF
EEM
|
+$35.8B |
| 2 |
Apple
AAPL
|
+$1.83B |
| 3 |
Invesco QQQ Trust
QQQ
|
+$913M |
| 4 |
Microsoft
MSFT
|
+$856M |
| 5 |
Bank of America
BAC
|
+$792M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 49.47% |
| 2 | Technology | 19.84% |
| 3 | Consumer Discretionary | 7.61% |
| 4 | Financials | 5.61% |
| 5 | Communication Services | 3.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2526
Pacific Biosciences
PACB
$596M
| $2.17M | ﹤0.01% |
914,004
+637,016
| +230% | +$899K |
2013 Q2
53 quarters
|
|
2527
Univest Financial
UVSP
$1.1B
| $2.16M | ﹤0.01% |
52,596
+3,172
| +6% | +$136K |
2016 Q1
42 quarters
|
|
2528
Ryerson Holding Corp
RYZ
$1.58B
| $2.15M | ﹤0.01% |
91,427
+37,488
| +70% | +$993K |
2016 Q3
40 quarters
|
|
2529
CALL
Cisco
CSCO
$396B
| $2.15M | ﹤0.01% |
20,000
-175,400
| -90% | -$19.8M |
2025 Q2
5 quarters
|
|
2530
Old Second Bancorp
OSBC
$1.24B
| $2.15M | ﹤0.01% |
87,796
+193
| +0.2% | +$4.78K |
2016 Q2
41 quarters
|
|
2531
CALL
Remitly
RELY
$4.85B
| $2.15M | ﹤0.01% |
100,600
+600
| +0.6% | +$14.3K |
2026 Q2
1 quarter
|
|
2532
Avalo Therapeutics
AVTX
$452M
| $2.14M | ﹤0.01% |
139,801
+121,990
| +685% | +$2.24M |
2025 Q3
4 quarters
|
|
2533
Silence Therapeutics
SLN
$1.23B
| $2.14M | ﹤0.01% |
195,958
+192,540
| +5,633% | +$2.34M |
2024 Q1
10 quarters
|
|
2534
PUT
First Solar
FSLR
$18.6B
| $2.14M | ﹤0.01% |
12,200
-174,400
| -93% | -$36.9M |
2023 Q4
11 quarters
|
|
2535
CALL
NetApp
NTAP
$35.7B
| $2.12M | ﹤0.01% |
+10,100
| New | +$1.86M |
2026 Q3
0 quarters
|
|
2536
Acadia Pharmaceuticals
ACAD
$3.14B
| $2.12M | ﹤0.01% |
105,058
+66,962
| +176% | +$1.8M |
2013 Q2
53 quarters
|
|
2537
CALL
Axon Enterprise
AXON
$25.3B
| $2.11M | ﹤0.01% |
+5,000
| New | +$2.7M |
2026 Q3
0 quarters
|
|
2538
Aura Minerals Inc
AUGO
$6.54B
| $2.11M | ﹤0.01% |
26,824
-10,886
| -29% | -$796K |
2025 Q4
3 quarters
|
|
2539
ENI
E
$80.3B
| $2.11M | ﹤0.01% |
38,855
+9,798
| +34% | +$521K |
2026 Q1
2 quarters
|
|
2540
Arcutis Biotherapeutics
ARQT
$3.55B
| $2.11M | ﹤0.01% |
79,718
+32,093
| +67% | +$839K |
2022 Q1
18 quarters
|
|
2541
FLEX LNG
FLNG
$1.37B
| $2.11M | ﹤0.01% |
68,454
+6,810
| +11% | +$211K |
2019 Q2
29 quarters
|
|
2542
CSW Industrials
CSW
$4.6B
| $2.1M | ﹤0.01% |
7,303
+3,009
| +70% | +$919K |
2016 Q3
40 quarters
|
|
2543
Wendy's
WEN
$1.62B
| $2.1M | ﹤0.01% |
329,669
+69,974
| +27% | +$540K |
2013 Q2
53 quarters
|
|
2544
Allied Gold Corp
AAUC
$2.93B
| $2.1M | ﹤0.01% |
100,550
+28,666
| +40% | +$632K |
2025 Q4
3 quarters
|
|
2545
iShares Core S&P Mid-Cap ETF
IJH
$125B
| $2.1M | ﹤0.01% |
29,163
-399,237
| -93% | -$30.1M |
2013 Q2
53 quarters
|
|
2546
Simmons First National
SFNC
$3.38B
| $2.1M | ﹤0.01% |
92,788
+23,573
| +34% | +$545K |
2016 Q2
41 quarters
|
|
2547
Ichor Holdings
ICHR
$1.37B
| $2.09M | ﹤0.01% |
33,845
+1,349
| +4% | +$94K |
2016 Q4
39 quarters
|
|
2548
Summit Therapeutics
SMMT
$12.6B
| $2.09M | ﹤0.01% |
123,360
-86,847
| -41% | -$1.3M |
2022 Q1
18 quarters
|
|
2549
PUT
Southwest Airlines
LUV
$22.7B
| $2.08M | ﹤0.01% |
+50,000
| New | +$2.19M |
2026 Q3
0 quarters
|
|
2550
Kodiak Sciences
KOD
$6.72B
| $2.07M | ﹤0.01% |
21,813
+773
| +4% | +$31.9K |
2019 Q1
30 quarters
|
|
Similar funds
Barclays's Q3 2026 Portfolio in Review
As of Q3 2026, Barclays held 5,855 positions worth $500B, down 4% from $521B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Barclays withdrew a net $19B in Q3 2026, closing 474 positions and reducing 1,494 holdings. Its most notable exit was ExxonMobil, an estimated $761M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 49% of assets, down from 55% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Barclays opened a new position in iShares Broad USD High Yield Corporate Bond ETF worth $199M.
- Barclays's largest Q3 2026 buy was iShares Broad USD High Yield Corporate Bond ETF: 5,582,517 shares worth $199M.
- Barclays added most to Tesla in Q3 2026, an estimated $17.5B increase.
- Barclays's biggest Q3 2026 reduction was iShares MSCI Emerging Markets ETF, cutting an estimated $35.8B.
- Barclays fully exited ExxonMobil in Q3 2026, selling an estimated $761M.
- Barclays's ten largest holdings make up 40% of its $500B portfolio in Q3 2026.
- Barclays opened 525 new positions and closed 474 in Q3 2026.
- Barclays's portfolio value fell 4% quarter-over-quarter to $500B.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.